Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
174 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Osteoarthritis Pain - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Osteoarthritis Pain - Pipeline Review, H1 2015', provides an overview of the Osteoarthritis Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Osteoarthritis Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Osteoarthritis Pain Overview 8 Therapeutics Development 9 Pipeline Products for Osteoarthritis Pain - Overview 9 Pipeline Products for Osteoarthritis Pain - Comparative Analysis 10 Osteoarthritis Pain - Therapeutics under Development by Companies 11 Osteoarthritis Pain - Therapeutics under Investigation by Universities/Institutes 15 Osteoarthritis Pain - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Osteoarthritis Pain - Products under Development by Companies 20 Osteoarthritis Pain - Products under Investigation by Universities/Institutes 23 Osteoarthritis Pain - Companies Involved in Therapeutics Development 24 AbbVie Inc. 24 Actavis plc 25 Addex Therapeutics Ltd 26 Afferent Pharmaceuticals, Inc. 27 Akron Molecules AG 28 Amgen Inc. 29 Ampio Pharmaceuticals, Inc. 30 AnaMar AB 31 Antibe Therapeutics, Inc. 32 Astellas Pharma Inc. 33 Boehringer Ingelheim GmbH 34 Bone Medical Limited 35 Eli Lilly and Company 36 Flexion Therapeutics, Inc. 37 Grunenthal GmbH 38 iCeutica, Inc. 39 Iroko Pharmaceuticals, LLC 40 Nektar Therapeutics 41 Nuvo Research Inc. 42 Pfizer Inc. 43 Phosphagenics Limited 44 Pozen, Inc. 45 Purdue Pharma L.P. 46 Regeneron Pharmaceuticals, Inc. 47 Rottapharm SpA 48 Teva Pharmaceutical Industries Limited 49 Osteoarthritis Pain - Therapeutics Assessment 50 Assessment by Monotherapy Products 50 Assessment by Combination Products 51 Assessment by Target 52 Assessment by Mechanism of Action 55 Assessment by Route of Administration 57 Assessment by Molecule Type 59 Drug Profiles 61 (lidocaine + tetracaine) - Drug Profile 61 A-889425 - Drug Profile 63 AAT-008 - Drug Profile 64 ADX-71441 - Drug Profile 65 AF-219 - Drug Profile 66 AKR-202 - Drug Profile 68 AMAP-102 - Drug Profile 69 Ampion - Drug Profile 71 AQU-010 - Drug Profile 73 AS-288640100 - Drug Profile 74 ATB-346 - Drug Profile 75 BI-1026706 - Drug Profile 77 calcitonin - Drug Profile 78 cebranopadol - Drug Profile 80 celecoxib - Drug Profile 82 CGS-125 - Drug Profile 83 CRB-0022 - Drug Profile 84 CRB-0089 - Drug Profile 85 duloxetine hydrochloride DR - Drug Profile 86 ELS-130 - Drug Profile 88 fasinumab - Drug Profile 89 fulranumab - Drug Profile 91 FX-005 - Drug Profile 94 grapiprant - Drug Profile 95 ibuprofen - Drug Profile 97 ibuprofen - Drug Profile 98 LY-2951742 - Drug Profile 99 meloxicam - Drug Profile 101 naproxen sodium - Drug Profile 103 NEO-5024 - Drug Profile 105 NEO-6860 - Drug Profile 106 NKTR-181 - Drug Profile 107 OLT-1177 - Drug Profile 109 onabotulinumtoxin A - Drug Profile 110 oxycodone ER - Drug Profile 112 PA-300 - Drug Profile 114 PA-300 DR - Drug Profile 116 PA-65020 - Drug Profile 117 Small Molecules to Block Calcium Ion Channel for Osteoarthritis Pain - Drug Profile 118 Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile 119 Small Molecules to Inhibit PDE2 for Osteoarthritis Pain - Drug Profile 120 tanezumab - Drug Profile 121 triamcinolone acetonide sodium phosphate SR - Drug Profile 123 TV-45070 - Drug Profile 124 V-116517 - Drug Profile 125 VLNX-4975 - Drug Profile 126 Osteoarthritis Pain - Recent Pipeline Updates 127 Osteoarthritis Pain - Dormant Projects 156 Osteoarthritis Pain - Discontinued Products 161 Osteoarthritis Pain - Product Development Milestones 163 Featured News & Press Releases 163 Appendix 170 Methodology 170 Coverage 170 Secondary Research 170 Primary Research 170 Expert Panel Validation 170 Contact Us 170 Disclaimer 171
List of Tables Number of Products under Development for Osteoarthritis Pain, H1 2015 12 Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H1 2015 13 Number of Products under Development by Companies, H1 2015 15 Number of Products under Development by Companies, H1 2015 (Contd..1) 16 Number of Products under Development by Companies, H1 2015 (Contd..2) 17 Number of Products under Investigation by Universities/Institutes, H1 2015 18 Comparative Analysis by Late Stage Development, H1 2015 19 Comparative Analysis by Clinical Stage Development, H1 2015 20 Comparative Analysis by Early Stage Development, H1 2015 21 Comparative Analysis by Unknown Stage Development, H1 2015 22 Products under Development by Companies, H1 2015 23 Products under Development by Companies, H1 2015 (Contd..1) 24 Products under Development by Companies, H1 2015 (Contd..2) 25 Products under Investigation by Universities/Institutes, H1 2015 26 Osteoarthritis Pain - Pipeline by AbbVie Inc., H1 2015 27 Osteoarthritis Pain - Pipeline by Actavis plc, H1 2015 28 Osteoarthritis Pain - Pipeline by Addex Therapeutics Ltd, H1 2015 29 Osteoarthritis Pain - Pipeline by Afferent Pharmaceuticals, Inc., H1 2015 30 Osteoarthritis Pain - Pipeline by Akron Molecules AG, H1 2015 31 Osteoarthritis Pain - Pipeline by Amgen Inc., H1 2015 32 Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 33 Osteoarthritis Pain - Pipeline by AnaMar AB, H1 2015 34 Osteoarthritis Pain - Pipeline by Antibe Therapeutics, Inc., H1 2015 35 Osteoarthritis Pain - Pipeline by Astellas Pharma Inc., H1 2015 36 Osteoarthritis Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2015 37 Osteoarthritis Pain - Pipeline by Bone Medical Limited, H1 2015 38 Osteoarthritis Pain - Pipeline by Eli Lilly and Company, H1 2015 39 Osteoarthritis Pain - Pipeline by Flexion Therapeutics, Inc., H1 2015 40 Osteoarthritis Pain - Pipeline by Grunenthal GmbH, H1 2015 41 Osteoarthritis Pain - Pipeline by iCeutica, Inc., H1 2015 42 Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals, LLC, H1 2015 43 Osteoarthritis Pain - Pipeline by Nektar Therapeutics, H1 2015 44 Osteoarthritis Pain - Pipeline by Nuvo Research Inc., H1 2015 45 Osteoarthritis Pain - Pipeline by Pfizer Inc., H1 2015 46 Osteoarthritis Pain - Pipeline by Phosphagenics Limited, H1 2015 47 Osteoarthritis Pain - Pipeline by Pozen, Inc., H1 2015 48 Osteoarthritis Pain - Pipeline by Purdue Pharma L.P., H1 2015 49 Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 50 Osteoarthritis Pain - Pipeline by Rottapharm SpA, H1 2015 51 Osteoarthritis Pain - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 52 Assessment by Monotherapy Products, H1 2015 53 Assessment by Combination Products, H1 2015 54 Number of Products by Stage and Target, H1 2015 56 Number of Products by Stage and Mechanism of Action, H1 2015 59 Number of Products by Stage and Route of Administration, H1 2015 61 Number of Products by Stage and Molecule Type, H1 2015 63 Osteoarthritis Pain Therapeutics - Recent Pipeline Updates, H1 2015 130 Osteoarthritis Pain - Dormant Projects, H1 2015 159 Osteoarthritis Pain - Dormant Projects (Contd..1), H1 2015 160 Osteoarthritis Pain - Dormant Projects (Contd..2), H1 2015 161 Osteoarthritis Pain - Dormant Projects (Contd..3), H1 2015 162 Osteoarthritis Pain - Dormant Projects (Contd..4), H1 2015 163 Osteoarthritis Pain - Discontinued Products, H1 2015 164 Osteoarthritis Pain - Discontinued Products (Contd..1), H1 2015 165
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
